▎药明康德内容团队编辑

图片来源：123RF

药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。

▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息

参考资料：

[1] Milani C, Duranti S, Bottacini F, et al. The First Microbial Colonizers of the Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. Microbiol Mol Biol Rev. 2017 Nov 8;81(4):e00036-17. Doi: 10.1128/MMBR.00036-17

[2] Julie E. Button, et al. Dosing a synbiotic of human milk oligosaccharides and B. infantis leads to reversible engraftment in healthy adult microbiomes without antibiotics. Cell Host & Microbe,Volume 30, Issue 5, 2022. Doi.org/10.1016/j.chom.2022.04.001

[3] How Human Milk can Treat the Microbiome and Improve Outcomes without Antibiotics. Retrieved August 12, 2022，from https://www.biospace.com/article/got-milk-it-may-do-the-microbiome-good-and-help-treat-underserved-patients-/

[4] Study Published in the Journal Cell Host & Microbe Offers Proof of Concept That a Human Milk-Based Synbiotic Could Allow Therapeutic Manipulation of the Gut Microbiome. Retrieved May 3，2022，from https://www.biospace.com/article/releases/study-published-in-the-journal-cell-host-and-amp-microbe-offers-proof-of-concept-that-a-human-milk-based-synbiotic-could-allow-therapeutic-manipulation-of-the-gut-microbiome/

版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。